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b2-Microglobulin increases the expression of vascular cell adhe- over time [3]. This suggests that b2m accumulates in other
sion molecule on human synovial fibroblasts. body compartments, such as the joint space. With its low
Background. b2-Microglobulin (b2m) amyloidosis is a de- molecular weight, it freely diffuses through the synovialstructive articular disease that affects patients on dialysis. The
membrane, and synovial fluid concentrations of b2m aredisease presentation is similar to other forms of arthritis in
also elevated [4]. The joint space is also the first andwhich adhesion molecules are felt to be pathogenic. Therefore,
we hypothesized that b2m directly increases the expression predominant site of deposition of b2m amyloid fibrils,
of vascular cell adhesion molecule-1 (VCAM-1) by synovial with cartilage and synovial membrane being the earliest
fibroblasts. We also examined the effect of alteration of b2m sites of deposition [5].by advanced glycation end products on this cellular response.
Studies have demonstrated that some of the b2m amy-Methods. Human synovial fibroblasts were isolated and in-
loid fibrils are altered with advanced glycation end prod-cubated with b2m with and without alteration with advanced
glycation end products. VCAM-1 expression was determined ucts (AGEs) [6, 7]. AGEs are a heterogenous group of
by immunohistochemistry, flow cytometry, and Western blot proteins that have been altered by the nonenzymatic
and Northern blot analyses.
addition of a carbohydrate adduct. AGE-b2m is a potentResults. b2m increased the protein expression of VCAM-1
stimulus of macrophage chemotaxis and cytokine re-by synovial fibroblasts in a dose-dependent manner. b2m al-
tered with advanced glycation end products had no effect. lease, raising the question of whether AGE alteration
However, all forms of b2m increased VCAM-1 mRNA. b2m of the b2m leads to amyloid deposition and/or is responsi-
also increased the adhesion of peripheral blood mononuclear ble for the late infiltration of macrophages into the de-
cells to synovial fibroblasts.
posits [6, 7]. However, a recent study of postmortem andConclusion. b2m directly increases the expression of VCAM-1
surgical specimens has demonstrated that b2m amyloidby synovial fibroblasts, indicating that synovial fibroblasts may
play a key role in the pathogenesis of b2m amyloidosis. fibrils are present without AGE alteration [8]. In addi-
tion, Hashimoto, Naiki, and Gejyo recently demon-
strated that in vitro b2m amyloid fibril extension is inhib-
b2-Microglobulin amyloidosis (Ab2m) is a destructive ited when the b2m is altered with AGE [9]. These studies
and debilitating articular disease that affects patients imply that AGE alteration occurs in situ after deposition
on long-term dialysis. The disease presents with carpal of the b2m amyloid [10]. Thus, while it is possible that
tunnel syndrome, bone cysts only near joints, synovial the in situ alteration of b2m with AGE may lead to
hypertrophy, and spondyloarthropathy [1]. The major macrophage infiltration, other factors also may be impor-
constituent protein of the amyloid deposits is b2m, a tant in causing the recurrent or persistent arthralgias,
nonglycosylated 11.8 kD polypeptide. Catabolism occurs joint stiffness, swelling of capsules and tendons, recur-
exclusively in the kidney, and the removal with dialysis rent joint effusions, and synovitis seen in patients with
cannot keep up with daily production [2]. As a result, end-stage renal disease.
serum levels in dialysis patients are 15 to 30 times greater Some of the clinical symptoms observed in Ab2m are
than normal. However, despite ongoing production and similar to rheumatoid arthritis (RA), and thus, many of
inadequate removal, serum levels of b2m do not increase the pathogenic mechanisms in RA may be important
in Ab2m as well. In RA, current theories support an
important role for the synovial intimal lining fibroblastsKey words: amyloidosis, dialysis amyloid, advanced glycation end prod-
ucts, hemodialysis, articular disease. as key in the early pathogenesis of the disease [11]. These
cells are known to produce cytokines, metalloprotei-Received for publication March 16, 2000
nases, and adhesion molecules such as vascular cell adhe-and in revised form October 18, 2000
Accepted for publication November 13, 2000 sion molecule-1 (VCAM-1). All of these are felt to be
pathogenic in RA [11–13]. On immunostaining of Ab2mÓ 2001 by the International Society of Nephrology
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deposits, there is increased expression of metalloprotei- man monocytes using the adherence method [18], al-
lowed them to differentiate to macrophage-like cells innases as well as adhesion molecules [14, 15]. We have
previously demonstrated that b2m induces the release of culture, and incubated them for 24 hours with no b2m
(control), or with 25 mg/mL fb2m and gb2m as per thematrix metalloproteinase-1 (MMP-1), but not its inhibi-
tor, tissue inhibitor of metalloproteinase (TIMP-1), from methods of Miyata et al and Matsuo et al [6, 18]. The
release of tumor necrosis factor-a (TNF-a) into the cul-human synovial fibroblasts (SFLs), leading to an increased
MMP-1/TIMP-1 ratio and uncontrolled proteolysis [16]. ture media was measured by enzyme-linked immunosor-
bent assay (R&D Systems, Minneapolis, MN, USA).The purpose of the present study was to determine
whether b2m directly increases the expression of the ad- Similar to previous reports [6, 18], the gb2m induced the
release of tenfold more TNF-a than control and fb2m.hesion molecule VCAM-1. To test this hypothesis, we
incubated human SFLs with b2m and b2m altered with
Isolation and culture of human synoviocytesAGE (AGE-b2m), and determined the expression of
VCAM-1 by immunohistochemistry, flow cytometry, and Human synovium was obtained from patients under-
going total knee or hip replacement for osteoarthritis,Western and Northern blot analyses.
as approved by our local Institutional Review Board.
Synovial tissue was minced, digested with collagenase
METHODS
(Wako, Richmond, VA, USA), and followed by trypsin
Isolation and purification of b2m and AGE-b2m (Sigma). The supernatant was collected. Collagenase ac-
tivity was quenched, and cells were pelleted and placedb2-Microglobulin was isolated from the ultrafiltrate of
a chronic (25 years) hemodialysis patient with documented in a T-25 flask in Dulbecco’s modified Eagle’s medium
(DMEM; GIBCO, Inc., Grand Island, NY, USA) withAb2m as previously described [16]. Briefly, dialysate ultra-
filtrate was concentrated, desalted, and then further puri- 20% fetal bovine serum (FBS). The cells were character-
ized by immunohistochemistry, flow cytometry, and bio-fied by isoelectric focusing. The b2m was then separated
into nonglycated and endogenously glycated b2m (AGE- chemical staining as previously described [16]. At pass
one, approximately 90% of the cells were macrophage-b2m) fractions by affinity chromatography on m-boronate
columns used for the detection of glycated hemoglobin, like, and 10% were fibroblast-like cells. As passages con-
tinued, the proportion of fibroblasts increased to 80 tothrough an adaptation of the methods of Silver et al [17],
using a 200 mmol/L glycine buffer, pH 8.5. The resultant 90% by pass 3, and thus, all experiments were performed
on pass 5 to 6 to ensure pure fibroblast-like cells. Theglycated b2m (gb2m; less than 0.1% of total) was re-
moved, and the remaining non-gb2m (ngb2m) was sepa- human SFLs were then cultured at 1 3 105 cells per well
in DMEM, with 20% FBS at 378C in 5% CO2 untilrated into three fractions. The first was incubated in the
presence of glycating buffer [1 3 phosphate-buffered confluent (3 to 4 days). The media were then changed
to control (no b2m), fb2m, gb2m, or ngb2m at varioussaline (PBS), 200 mmol/L D-glucose, 1.5 mmol/L phenyl-
methylsulfonyl fluoride (PMSF), 1 mmol/L ethylenedi- concentrations and times as described later in this article.
aminetetraacetic acid (EDTA); all from Sigma Chemi-
Immunohistochemistrycals, St. Louis, MO, USA] at 378C for 60 days, and
represents gb2m. The second was similarly incubated Synovial fibroblasts were incubated for 24 hours in
fb2m, gb2m, or ngb2m at 25 mg/mL and TNF-a at 100but without the glucose to serve as a control for long
incubation period and represents ngb2m. The last frac- ng/mL on cover glass Petri dishes. To determine the
specificity of the response, some SFLs were also incu-tion was neither incubated nor glycated and represents
fresh b2m (fb2m). Following the incubation, all three bated with cystatin C, a 13 kD protein that is markedly
elevated in patients with renal failure [19]. Cystatin Cfractions were then run on a Toxigel column (Sigma) to
remove any potential lipopolysaccharide (LPS) contami- at concentrations of 1, 5, and 10 mg/L was used (Calbio-
chem, San Diego, CA, USA). The cells were fixed withnation. The gb2m, but neither the ngb2m nor fb2m, fluo-
resced at 400 nm with excitation at 325 nm, typical for paraformaldehyde, extracted, blocked, and incubated
with primary antibody (polyclonal goat anti-humanglycated proteins, and only the gb2m reacted by Western
blot to an anti-AGE antibody (Altean, Inc., Ramsen, VCAM-1, R&D Systems) at 1:200 dilution for 45 minutes
at 378C. After washing, the secondary antibody (TexasNJ, USA) as previously described [16]. For comparative
purposes, the effect of b2m isolated from ultrafiltrate was Red conjugated donkey anti-goat; Molecular Probes, Eu-
gene, OR, USA) was added at 1:200 dilution and incu-compared with b2m isolated from human urine (Cortex
Biochemicals, San Leandro, CA, USA) in the induction bated for an additional 45 minutes at 378C. Cells were
washed, stained with Topro-3 nuclear dye, and visualizedof VCAM-1 expression by flow cytometry. There was
no difference in two separate experiments, which are with a MRC-1024 laser scanning confocal microscopy
(Bio-Rad, Hercules, CA, USA). Images were processedincluded in Table 2.
To assess the bioactivity of our gb2m, we isolated hu- on a Metamorph image analysis system.
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Flow cytometry of acid phenol and chloroform and was precipitated over-
night with isopropanol. RNA was quantitated by spectro-To examine the effect of b2m on the expression of
photometer at 260 nm. Thirty to forty micrograms ofVCAM-1 by SFLs over time, cells were incubated with
total RNA were electrophoresed in 1% agarose formal-fb2m, gb2m, or ngb2m at 25 mg/mL for 6, 12, 24 and 48
dehyde gel and transferred overnight to nitrocellulosehours, resuspended in PBS, and incubated with human
membrane with 20 3 standard saline citrate (SSC). TheIgG to block nonspecific binding for 20 minutes at 48C.
membrane was baked at 808C for one hour. The integrityAfter washing with 1% bovine serum albumin (BSA)
of RNA preparations and the extent of RNA transferin PBS, they were incubated with mouse anti-human
were estimated by viewing the ethidium bromide-stainedVCAM-1 conjugated to phycoerythrin (PE) fluorochrome
gel(s) and membrane(s). The membrane(s) was prehy-(Research Diagnostic, Inc., Pleasant Hill, NJ, USA) for
bridized at 428C in 50% formamide, 5 3 SSPE, 5 3one hour at 48C. An appropriate PE-congugated isotype
Denhart’s solution, 0.5% SDS, and 200 mg of denaturedcontrol antibody was used to determine the extent of
salmon sperm DNA/mL for six to eight hours. The hy-nonspecific staining of the SFLs with the mouse antibody.
bridization was carried overnight at 428C in 50% for-After washing, the nuclear dye 7-aminoactinomycin D
mamide, 5 3 SSPE, 2 3 Denhart’s solution, 0.1% SDS,(7-AAD) was added to the cells at a concentration of 5
and 100 mg of denatured salmon sperm DNA/mL. Themg/mL to determine the viability of the SFLs, and the
hybridization solution contained radiolabeled partialcells were analyzed by flow cytometry (Becton Dickinson
VCAM-1 cDNA (1 to 5 3 106 cpm/mL). The 524 bpFACScan, Mountain View, CA, USA). Cells were gated
VCAM-1 cDNA was labeled with 32P dCTP using ran-to exclude nonviable cells that stained positive with
dom primer method. The membranes were washed twice7-AAD. VCAM-1 expression was then quantitated on
at room temperature in 2 3 SSC, 0.5% SDS for 30 min-the viable cells (7-AAD dim staining cells).
utes, and twice at 608C for 30 minutes in 0.1 3 SSC,To determine the concentration effect of b2m on SFLs, 0.5% SDS. The membranes were then examined by auto-cells were incubated with fb2m, gb2m, or ngb2m at 1, 5, radiography. RNA was sized by comparison with 28S10, 25, or 50 mg/mL for 24 hours and analyzed by flow
and 18S rRNA and RNA size ladder. The membrane wascytometry. Finally, to determine the interpatient vari-
stripped and reprobed with control cDNA (GAPDH) to
ability in the expression of VCAM-1, SFLs from 11 pa-
confirm the equivalent loading of RNA.
tients were examined after incubation with 25 mg/mL
The VCAM-1 cDNA used for hybridization was am-
fb2m, gb2m, ngb2m or 100 ng/mL TNF-a for 24 hours. plified by reverse transcriptase-polymerase chain reac-
Previous experiments have demonstrated a less than tion (RT-PCR) from TNF-a–treated SFLs. First-strand
10% variation in mean fluorescence intensity (MFI) be- cDNA was synthesized using Reverse Transcription
tween the incubations for each patient. System from Promega (Promega Corporation, Madison,
WI, USA). In brief, total RNA (0.5 mg) was incubatedWestern blot analysis
at 428C with 10 mmol/L Tris-HCl (pH 9.0), 50 mmol/L
To determine VCAM-1 expression from cell lysate, KCl, 1 mmol/L dNTP, 0.5 mg oligo(dT)15 primers, 1 U
cells were incubated with 25 mg/mL fb2m, gb2m, ngb2m RNAsin/mL RT-PCR reaction, and 15 U AMV reverse
or 100 ng/mL TNF-a for 24 hours. Media were decanted, transcriptase/mg total RNA for one hour. The reaction
and cells were lyzed using ultrasound. Equal amounts was terminated by heating at 908C for five minutes. The
of protein were loaded into 10% sodium dodecyl sulfate cDNA was ethanol precipitated overnight at 208C and
(SDS)-polyacrylamide gradient gel and then electropho- resuspended in dH2O. Five to 10 mL of the cDNA were
retically transblotted to a nitrocellulose membrane for used to amplify the VCAM-1 by PCR using the primers
Western blot analysis. Goat anti-human VCAM-1 anti- (forward 59-CATGACCTGTTCCAGCGAGGGT-39 and
body (R&D Systems) was used as primary antibody fol- reverse 59-CATTCACGAGGCCACCACTCAT-39). The
lowed by horseradish peroxidase (HRP)-conjugated PCR products were fractionated on an agarose gel. The
donkey anti-goat IgG as secondary antibody (Jackson bands were cut, and the DNA was purified using Pro-
ImmunoResearch Labs, West Grove, PA, USA), fol- mega Wizard PCR-DNA purification kit.
lowed by 4-chloro-1-naphthol development.
Adhesion assay
RNA preparation and Northern analysis To determine the capacity of peripheral blood mono-
Total cellular RNA was extracted from the cells by nuclear cells (PBMCs) to adhere to SFLs after exposure
adaptations of the methods of Chomczynski and Sacchi to b2m, PBMCs were isolated from healthy individuals
[20]. Cells were scraped from 75 cm2 flasks with homoge- by Ficoll-Hypaque gradient (Sigma) and fluorescently
nizing buffer [4 mol/L guanidinium thiocyanate, 25 mmol/L tagged by 5(6)-carboxyfluorescein diacetate (Sigma).
sodium citrate (pH 7.0), 0.5% sarcosyl, 0.1 mol/L 2-mer- SFLs were cultured on chamber slides at equal densities
and incubated with 25 mg/mL b2m or 100 ng/mL TNF-acaptoethanol]. The RNA was extracted with equal parts
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Fig. 1. Immunohistochemistry. Human syno-
vial fibroblast-like cells (SFLs) were incubated
with fresh (fb2m), glycated (gb2m), or nongly-
cated (ngb2m) b2-microglobulin for 24 hours
at a concentration of 25 mg/mL, and immuno-
histochemistry was performed. The nuclei
were stained with Topro-3. (a) Negative con-
trol (no primary antibody). (b) Control (no
b2m). (c) fb2m. (d) gb2m. (e) ngb2m. (f) Tumor
necrosis factor-a (TNF-a). There was expres-
sion noted with fb2m and ngb2m, but not with
gb2m. TNF-a at 100 ng/mL was used as a posi-
tive control. The expression of the adhesion
molecules was especially dramatic in the den-
dritic processes.
for 24 hours. The media were then changed to DMEM, ng/mL TNF-a, the positive control [11, 12]. Cystatin C
did not increase VCAM-1 expression at any of the con-and 106 PBMCs were added for one hour. The coculture
was washed to decant the nonadhering PBMC, and the centrations used.
number of PBMCs adhering to SFLs was quantitated by
Flow cytometrycounting under fluorescence microscopy in four randomly
selected high-power fields (HPFs) for each condition. Flow cytometry was performed to quantitate the in-
creased expression of VCAM-1 in response to b2m. Fig-
Statistical analysis ure 2 shows representative flow cytometry histograms
of SFLs from one patient with fb2m, gb2m, or ngb2m atTo control for the variability between patients in the
expression of adhesion molecules, the MFI results were 25 mg/mL for 24 hours. TNF-a was used as a positive
expressed as the percentage of the MFI for the control control at 100 ng/mL. The expression of VCAM-1 was
sample run for each patient. Group means were com- increased in cells incubated with fb2m and ngb2m, but
pared by analysis of variance (ANOVA) with Fisher’s post not in cells incubated with gb2m. For comparison pur-
hoc analysis. A two-factor repeated-measures ANOVA poses and statistical analysis, the MFI was utilized in
was used to analyze the results obtained from the concen- subsequent experiments.
tration experiments and the relationship with the type The synovial fibroblasts from two patients incubated
of b2m. The results are expressed as mean 6 SEM, with with fb2m or ngb2m at a concentration of 25 mg/mL
P , 0.05 considered significant (StatView and Super showed an increase with time in VCAM-1 expression,
ANOVA; Abacus Concepts, Berkeley, CA, USA). whereas gb2m was similar to control (Table 1). The effect
of b2m on the expression of VCAM-1 at different concen-
trations was examined by incubating the SFLs from four
RESULTS
different patients with fb2m, gb2m or ngb2m at 1, 5, 10,
Immunohistochemistry 25, or 50 mg/mL for 24 hours. Incubation with either
fb2m or ngb2m showed a dose-dependent increase inThe expression of VCAM-1 in SFLs was increased
after incubation with fb2m and ngb2m at 25 mg/mL for VCAM-1 expression, whereas gb2m had no effect at any
concentration (P , 0.01; Fig. 3).24 hours (Fig. 1). In contrast, the SFLs incubated with
gb2m demonstrated no increased expression of this adhe- To determine the interpatient variability in the expres-
sion of VCAM-1, SFLs from 11 patients were incubatedsion molecule compared with control. The expression in
the dendritic processes was especially dramatic, although with fb2m or gb2m for 24 hours at a concentration of
25 mg/mL. The flow cytometry MFI results (Table 2)it varied between cells. The expression of VCAM-1 in
response to fb2m was similar to that observed with 100 indicate significant variability between patients in the
Fig. 3. Dose-response of VCAM-1 expression following incubation of
the SFLs with fb2m (j), gb2m (s), or ngb2m (m) at different concentra-
tions for 24 hours. Incubation with either fb2m or ngb2m resulted in a
dose-dependent increase in VCAM-1 expression reaching the highest
intensity at 50 mg/mL, whereas gb2m had no effect at any concentration
(P , 0.01). N 5 4 at each concentration from four different patients.
expression of VCAM-1, both at baseline and following
stimulation with b2m or TNF-a.
Western blot analysis
Synovial fibroblasts were incubated for 24 hours with
fb2m, gb2m, ngb2m at a concentration of 25 mg/mL or
TNF-a. Western blot analysis showed dense bands at
the appropriate dual molecular weights of 90 and 110
kD, corresponding to VCAM-1, from SFLs incubated
with fb2m or ngb2m, but not gb2m (Fig. 4). The increase
was also noted with TNF-a. Figure 4 is a representative
Western blot of four different experiments.
Northern blot analysis
Northern blot analysis detected increased mRNA ex-
pression of VCAM-1 after incubating SFLs for 24 hours
with fb2m, gb2m, and ngb2m at 25 mg/mL, although there
was a trend toward greater expression with the fb2m and
ngb2m compared with gb2m. Figure 5 is a representative
Northern blot and densitometry from one patient. The
VCAM-1/GAPDH ratio as assessed by densitometry for
the combined results of three different Northern blot
b
Fig. 2. Flow cytometry histograms. Histograms of flow cytometry of
SFLs from a representative patient, stained with phycoerythrin (PE)-
conjugated anti–vascular cell adhesion molecule-1 (VCAM-1) antibody
after 24 hours of incubation with fb2m, gb2m, or ngb2m at a concentration
of 25 mg/mL. TNF-a at a concentration of 100 ng/mL was used as a
positive control. Mean fluorescence intensity (MFI) was determined
after excluding nonviable cells using the nuclear dye 7-aminoactinomy-
cin D (7-AAD). Note the significant shift to the right on the x axis
indicating higher channel numbers and, hence, increased intensity of
the VCAM-1 expression with fb2m or ngb2m but not with the gb2m.
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Table 1. Time-dependent release of vascular cell adhesion molecule (VCAM-1) from synovial fibroblasts from two patients
Patient 1 Patient 2
Mean fluorescence intensity Mean fluorescence intensity
(% control for that time point) (% control for that time point)
Time Control fb2m gb2m ngb2m Control fb2m gb2m ngb2m
6 hours 11 13 (118) 10 (91) 12 (109) 21 24 (114) 17 (81) 23 (110)
12 hours 9 11 (122) 9 (100) 11 (122) 27 31 (115) 22 (82) 33 (122)
24 hours 10 13 (130) 10 (100) 13 (130) 24 33 (138) 23 (96) 34 (142)
48 hours 8 13 (163) 8 (100) 12 (150) 27 50 (185) 27 (100) 45 (167)
Abbreviations are: fb2m, fresh b2-microglobulin (b2m); gb2m, glycated b2m; ngb2m, nonglycated b2m.
Table 2. Mean fluorescence intensity (MFI) of VCAM-1 for 11 interpatient variability in VCAM-1 expression has also
patients following 24 hours of incubation of synovial fibroblasts
previously been reported by other investigators examin-(SFLs) with control (no b2m), fresh b2m (fb2m), or glycated (gb2m)
at 25 mg/mL, or TNF-a at a concentration of 100 ng/mL ing both rheumatoid and osteoarthritis SFLs [21, 22].
Presumably, the severity of underlying disease, currentVCAM-1 expression (MFI)
therapy, and other coexistent illness alters expression.
Patient Control fb2m gb2m TNF-a Vascular cell adhesion molecule-1 is an adhesion mol-
1 110 146 103 292 ecule that belongs to the immunoglobulin superfamily2 66 126 61 216
that consists of a large number of molecules involved in3 27 32 20 160
4 89 194 89 336 immunity and inflammation, many of which function in
5 165 303 163 242 cell adhesion [12, 13]. Adhesion molecules, especially6 119 144 121 109
VCAM-1, have been shown to have a significant role in7 26 41 36 104
8 174 199 115 265 the pathogenesis of inflammatory articular diseases such
9 16 21 13 75
as RA [13, 22], and are believed responsible for the10 89 185 80 320
11 173 240 114 264 migration and adhesion of inflammatory cells into the
Mean6SE 96618 148627a 83614 217628a,b joint [23–25]. Initial theories on the pathogenesis of RA
Note the interpatient variability in baseline expression and after stimulation proposed the lymphocytes to be the initial “activated”
with fb2m or TNF-a.
cell with subsequent infiltration into the joint. However,a P , 0.05 compared with control and gb2m
b P , 0.05 compared with b2m recent investigators have proposed that the SFL may
actually be the initial cell to be activated, with secondary
lymphocytic infiltration [11]. This recent change in pro-
posed pathogenesis in part is explained by the findingsanalyses was 0.333 6 0.102 for control, 1.590 6 0.771 for
of increased expression of adhesion molecules in thefb2m, 1.167 6 0.565 for gb2m, and 1.492 6 0.652 for
SFLs. The adhesion molecules can then lead to cell pro-ngb2m (P , 0.05 for all compared with control, P 5 NS
liferation, metalloproteinase and cytokine release, andfor comparison of different types of b2m).
adjacent tissue destruction observed in RA [13, 24]. Our
findings on the effects of b2m on the SFL, includingAdhesion assay
increased VCAM-1 and MMP-1/TIMP-1 expression [16],Peripheral blood mononuclear cells isolated from
together with the work of Migita et al demonstratinghealthy individuals showed a significant increase in the
increased cyclooxygenase-2 (COX-2) expression [26], in-number of PBMCs that adhere to SFLs previously incu-
dicate that the SFL is similarly “activated” in responsebated with 25 mg/mL fb2m for 24 hours (P , 0.01; Fig.
to b2m. Thus, b2m itself may elicit the same cascade of6). The number of cells adhering to SFLs incubated with
events as does the inflammatory cell infiltrate in RA.25 mg/mL of fb2m was similar to that observed with TNF-a.
Vascular cell adhesion molecule-1 was initially felt to
be primarily important in the recruitment of mononu-
DISCUSSION clear cells to areas of inflammation [23–25]. Indeed, we
also found that the incubation of SFLs in the presenceThis study demonstrates that the incubation of human
of b2m led to increased adherence of PBMCs, supportingosteoarthritic SFLs with b2m increases the protein ex-
this function of VCAM-1 and possibly explaining thepression of VCAM-1. The response increased with time
monocyte/macrophage infiltration that is observed inand was dose dependent. The expression was blocked by
Ab2m [5, 8, 15]. However, given that monocyte/macro-the alteration of b2m with AGE. There was interpatient
phage infiltration occurs only late in the disease course,variability in the basal expression of VCAM-1 as well
as in the magnitude of b2m-induced expression. This our in vitro findings do not fully explain this pathologic
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Fig. 4. A representative Western blot analysis. SFLs were incubated
with 25 mg/mL fb2m, gb2m, ngb2m, or 100 ng/mL TNF-a for 24 hours
and were lysed and loaded into 10% SDS-polyacrylamide gel electro-
phoresis at 18 mg of protein per lane. The gel was then transferred
to nitrocellulose, incubated with goat anti-human VCAM-1 antibody
followed by HRP-conjugated donkey anti-goat IgG. Dense bands were
seen at molecular weights of 90 and 110 kD corresponding to VCAM-1.
Expression of VCAM-1 was increased in cells incubated with fb2m,
ngb2m, or TNF-a, compared with control. In contrast, gb2m did not
increase the protein expression of VCAM-1. The experiment was re-
peated using SFLs from four different patients with consistent results.
observation. However, in addition to the cellular recruit-
ment function, recent studies have demonstrated that
VCAM-1 may also be important in many other impor-
tant biologic responses. For example, in the rheumatoid
nodule, VCAM-1 was found to be a marker of SFL
differentiation [27]. In mouse, the formation of osteo-
clasts from stromal cells was found to be dependent on
the expression of VCAM-1 [28]. Finally, a coculture of
chondrocytes and SFLs demonstrated that chondrocyte
Fig. 5. Northern blot analysis. Northern blot analysis was performeddegradation by SFLs was also dependent on VCAM-1 to detect mRNA expression of VCAM-1 by SFLs after a 24 hours of
and involved the release of proteinases [29]. Thus, the incubation with 25 mg/mL of fb2m, gb2m, or ngb2m. A representative
Northern blot and band densitometry are shown. fb2m, ngb2m, androle of VCAM-1 in tissue differentiation and degrada-
gb2m all resulted in an increase in mRNA expression of VCAM-1tion is becoming increasingly prominent and may be of compared with control, although there was a trend toward increased
relevance in the pathologic changes observed in cartilage expression with fb2m compared with gb2m.
and bone in b2m amyloidosis. Our study suggests a possi-
ble role of SFLs themselves in the destructive process
in this disease due to the effects induced by b2m expo-
sure, apart from the destruction induced by inflammatory
cell infiltration.
Interestingly, the AGE modification of the b2m re-
sulted in inhibition of the protein expression of VCAM-1.
The alteration of proteins with AGE is increased in dia-
betes, renal failure, and aging and is hypothesized to
account for a variety of disease states [reviewed in 30].
In vitro studies have demonstrated that AGE-b2m stimu-
lates the chemotaxis of macrophage/monocytes prefer-
entially over non-AGE-b2m (fb2m), with subsequent re-
lease of cytokines [6, 7, 18]. However, these results were
not specific for AGE-b2m, as AGE-albumin induced sim-
ilar results [6, 7, 18]. A recent histopathologic study of
dialysis patients demonstrated the presence of AGE-b2m
preferentially in advanced amyloid deposits, whereas
early b2m amyloid deposits were not altered with AGE
[8]. In addition, Hashimoto, Naiki, and Gejyo recently
found that the alteration of b2m amyloid fibrils with AGE Fig. 6. Adhesion assay. Peripheral blood mononuclear cells (PBMCs)
inhibited extension of the amyloid fibrils in vitro [9]. These were counted and coincubated with SFLs previously exposed to 25
mg/mL fb2m for 24 hours and to SFLs from the same patients exposedresults indicate that AGE alteration of b2m is likely to
to 100 ng/mL TNF-a. The number of PBMCs adhering was quantitatedoccur in situ, after deposition of b2m in the form of amyloid and showed an increased number of PBMCs adhering to SFLs exposed
to b2m compared with control (P , 0.05; N 5 9 from 7 patients).fibrils as suggested by Gejyo [10]. Our finding that AGE-
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b2m attenuated the protein expression of VCAM-1 on APPENDIX
SFLs indicates that the SFLs themselves might have an Abbreviations used in this article are: 7-AAD, 7-aminoactinomycin D;
Ab2m, b2-microglobulin amyloidosis; AGE, advanced glycation endimportant initial role in the pathogenesis of this disease,
product; b2m, b-2-microglobulin; COX-2, cyclooxygenase-2; fb2m, freshbefore alteration of the b2m with AGE occurs.
b2-microglobulin; gb2m, glycated b2-microglobulin; HPF, high powerSimilar to our VCAM-1 results, we found that gb2m field; HRP, horseradish peroxidase; MFI, mean fluorescence intensity;
MMP-1, matrix metalloproteinase-1; ngb2m, nonglycated b2-microglob-resulted in decreased release of MMP-1 by SFLs, while
ulin; PBMC, peripheral blood mononuclear cells; PE, phycoerythrin;the fb2m led to an increase in the MMP-1 release and RA, rheumatoid arthritis; RAGE, receptor for advanced glycation
an elevated MMP-1/TIMP-1 ratio [16]. Interestingly, de- end products; SFLs, human synovial fibroblast-like cells; TIMP-1, tissue
inhibitor of metalloproteinase; TNF-a, tumor necrosis factor-a;spite the lack of response of gb2m in the induction of
VCAM-1, vascular cell adhesion molecule-1.protein synthesis, the mRNA expression for both VCAM-1
and MMP-1 was still greater than control [16]. In addi-
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